Home>IPO>AMI Organics Ltd.

AMI Organics IPO

AMI Organics Ltd.

₹14,472 /24 sharesMinimum Investment

IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE & NSE₹610₹910+₹300.00 (49.18%)

IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
1 Sep ‘21 - 3 Sep ‘21₹14,47224₹603 - ₹610
Issue SizeIPO Doc
569.63Cr
RHP PDFopen_in_new

Subscription Rate As on 3rd Sep 2021, 5:00 PM

  • Retail Individual Investor
    13.36x
  • Non-Institutional Investor
    154.81x
  • Qualified Institutional Buyers
    86.64x

About Company

AMI Organics Ltd. is one of the leading research and development-driven manufacturers of specialty chemicals with varied end usage. It is focused on the development and manufacturing of advanced pharmaceutical intermediates (API). It also manufactures key starting materials for agrochemical and fine chemicals. The company has developed and commercialized over 450 pharma intermediates for APIs across 17 key therapeutic areas since inception. It has strong focus on R&D across high margin therapeutic areas such as anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anticoagulant.
... Read More
Parent Organisation
AMI Organics Ltd.
Founded
2004

Strengths & Risks

  • add
    Strong and diversified product portfolio ably supported by strong R&D and process chemistry skills.
  • add
    Extensive geographical presence and diversified customer base with long-standing relationships.
  • add
    High entry barriers in the chemicals manufacturing industry in which the company operates.
  • add
    Strong sales and marketing capabilities.
  • add
    Consistent financial performance.
  • remove
    The company is subject to strict quality requirements, regular inspections, and audits
  • remove
    Dependency upon its quality controls and standards for the acceptability of its products
  • remove
    Non-compliance with and adverse changes in health, safety, labor, and environmental laws and other similar regulations applicable to its manufacturing operations
  • remove
    Dependency on certain therapeutic areas for deriving a significant portion of its revenue
  • remove
    Inability to identify and understand evolving industry trends, technological advancements, customer preferences, and develop new products to meet the demands of its customers
  • remove
    Any adverse developments or inability to enter into or maintain customer relationships
  • remove
    The geographic concentration of its manufacturing facilities in Gujarat
  • remove
    Company operates in a hazardous industry and is subject to certain business and operational risks consequent to its operations, such as the manufacture, usage and storage of various hazardous substances.
  • remove
    Any shortfall in the supply of its raw materials or an increase in the raw material cost may adversely affect the pricing and supply of its products.
  • remove
    Capital-intensive business.
  • remove
    Foreign exchange risks since the company exports products to around 25 countries.
  • remove
    Under-utilization of its manufacturing capacities and an inability to effectively utilize its expanded manufacturing capacities.

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2021 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 1.9.0
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES: ICICI PRUDENTIAL  | HDFC  | NIPPON INDIA  | ADITYA BIRLA SUN LIFE  | SBI  | UTI  | FRANKLIN TEMPLETON  | KOTAK MAHINDRA  | IDFC  | DSP  | AXIS  | TATA  | L&T  | SUNDARAM  | PGIM  | INVESCO  | LIC  | JM FINANCIAL  | BARODA PIONEER  | CANARA ROBECO  | HSBC  | IDBI  | INDIABULLS  | MOTILAL OSWAL  | BNP PARIBAS  | MIRAE ASSET  | PRINCIPAL  | BOI AXA  | UNION KBC  | TAURUS  | EDELWEISS  | NAVI  | MAHINDRA  | QUANTUM  | PPFAS  | IIFL  | Quant  | SHRIRAM  | SAHARA | ITI
ABOUT GROWW
keyboard_arrow_down
arrow_drop_down_circle